Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Galcanezumab (PFS vs Autoinjector) in Healthy Subjects
NCT02836613Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2016
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of galcanezumab in migraine (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Galcanezumab at 3360 hours and Area Under the Concentration Versus Time Curve From Time Zero to Infinity at 3360 hours. Started Jul 2016; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02836613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836613.